The impact of reimbursement negotiations on cost and availability of new pharmaceuticals: evidence from an online experiment

Table 2 Design of experiment (parameters per role and round)

State	Round	Reser-vation price¹	Price offer^1,2	Deciders				Receiver			Funders
				Regulator		Seller		Patient			2 Payers	2 Investors
				Benefit^1,2		Benefit^1,2		Survival (m)	Quality of Life (q)	Benefit¹	Benefit^1,3	Benefit^1,3
				fix	bonus	fix	bonus	Survival (m)	Quality of Life (q)	Benefit¹	Benefit^1,3	Benefit^1,3
State without product								0	50%	0
Initial state (SoC)	0	50	50	120	x-y	120	y-x	5	50%	25	240 - y	y
New product	1	x	y	120	x-y	120	y-x	8	50%	40	240 - y	y
	2	x	y	120	x-y	120	y-x	10	50%	50	240 - y	y
	3	x	y	120	x-y	120	y-x	12	50%	60	240 - y	y
	4	x	y	120	x-y	120	y-x	15	50%	75	240 - y	y
	5	x	y	120	x-y	120	y-x	17	50%	85	240 - y	y

1: for groups 3 and 4, amounts in ,000 $ (converted 100,000 $ = 1 US$ at the end of the experiment); for groups 5 and 6, amounts divided by 100 and displayed as $ (converted 1 $ = 1 US$ at the end of the experiment)
2: additional bonus for successful offer in second game (if agreement possible, y_S ≤ y_R)
3. in the first game players see resulting benefits for funders, based on the potential reservation price (240-x and x)
SoC, standard of care (status quo); m, survival in months; q, quality of life on a scale of 1–100%

ISSN: 2191-1991